Clinical Studies We Are Currently Enrolling For
Welcome to CIT’s Current Studies page, where your opportunity to shape the future of healthcare begins. By registering for our ongoing clinical studies, you become an essential participant in advancing medical knowledge and improving patient care. Our trials focus on diverse areas, from pain relief and treatment innovations to chronic condition management. Your involvement doesn’t just contribute to scientific progress; it’s a chance to prioritize your well-being and inspire healthcare breakthroughs. Join us in this transformative endeavor and make a lasting impact on the world of medicine. Your journey to better health starts here.
Osteoarthritis of Knee (OA)
Aim of this Phase 3, 16-week study is to assess the safety and efficacy of single injection of Lorecivivint/placebo in patients with moderate to severe osteoarthritis (OA) pain of the knee. Open to enrollment.
Hypertension
The purpose of the trial is to evaluate the Blood Pressure (BP) lowering effect of lorundrostat (an aldosterone synthase inhibitor), when administered on the background of a standardized antihypertensive medication regimen, in subjects with uncontrolled hypertension (SBP >140 mmHg (and/or DBP > 90 mmHg). Open to enrollment
Osteoarthritis of Knee (OA)
The purpose of this study is to assess the pain lowering effect of pentosan polysulfate sodium (PPS) for treatment of pain and improvement of function in adult participants with knee osteoarthritis (OA) pain. Open to enrollment.
Osteoarthritis of Knee (OA)
This phase 3 study is to assess the efficacy of X0002 spray for the relief of pain from osteoarthritis (OA) of the knee. Enrollment closed.
Type 2 Diabetes
This study is designed to investigate the efficacy and safety of once weekly IcoSema, which is a combination product of insulin icodec and semaglutide. IcoSema will be compared to daily insulin glargine 100 units/mL combined with insulin aspart, both treatment arms with or without oral anti-diabetic drugs, in participants with type 2 diabetes inadequately controlled with daily basal insulin. Enrollment closed.